Related Experiment Videos
LOW PROFILE BIOPROSTHESIS FOR CARDIAC VALVE REPLACEMENT: EARLY CLINICAL RESULTS.
Domingo Liotta1, Daniel Bracco, Helio Ferrari
1Division of Cardiovascular Surgery of the Italian Hospital, Buenos Aires, Argentina.
Cardiovascular Diseases
|January 1, 1977
Summary
This study on glutaraldehyde-treated porcine aortic xenografts found low operative mortality and thromboembolic complications, particularly after mitral valve replacement. Anticoagulant therapy is recommended for eight to twelve weeks postoperatively in mitral valve replacement patients.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
Background:
- Porcine aortic xenografts are used for cardiac valve replacement.
- Low-profile glutaraldehyde-treated xenografts offer unique characteristics.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel low-profile glutaraldehyde-treated porcine aortic xenograft.
- To assess operative mortality, thromboembolic complications, and other adverse events.
Main Methods:
- 100 patients underwent cardiac valve replacement between May 1976 and April 1977.
- Patients were categorized into four groups based on the procedure (isolated MVR, isolated AVR, combined, or associated procedures).
- Follow-up extended for 16 months, with assessment of mortality, thromboembolism, reoperation, and endocarditis.
Main Results:
- Overall operative mortality was 4%, with variations across patient groups.
- Late mortality was 1.02% in survivors.
- Thromboembolic complications occurred in 3% of patients, exclusively in the mitral valve replacement group (4.9% incidence).
- One patient required reoperation for periprosthetic leak; endocarditis incidence was 1.02%.
Conclusions:
- The glutaraldehyde-treated porcine aortic xenograft demonstrated acceptable early outcomes.
- Anticoagulant therapy for 8-12 weeks is recommended for mitral valve replacement patients receiving bioprosthetic valves.
- Further research may be warranted to optimize anticoagulation strategies and minimize embolic events.